Mr. Chair, I would like to thank all of our witnesses for being here today.
I will start my questions with Dr. Morgan.
Dr. Morgan, I know you have written about different models for pricing drugs and how they can better serve patients. Can you speak to how, with models based on fixed costs, a patient's ability to pay might apply in Canada? Is there room for such a system in the PMPRB's proposed model?